---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-001950"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2022-01-06T23:59:59+00:00"
generated_at: "2026-06-27T20:13:40.395223+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Hepion's lead NASH drug gets USAN name 'rencofilstat'

## Summary
- USAN Council adopted 'rencofilstat' as nonproprietary name for CRV431, Hepion's lead NASH/liver disease drug.
- The name will be used in future publications, conferences, and clinical development steps.
- Hepion is a clinical-stage biopharma focusing on AI-driven therapies for NASH and other liver diseases.

## SEC filing metadata
- accession: 0001104659-22-001950
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2022-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000110465922001950/0001104659-22-001950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000110465922001950/tm221986d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-001950
- JSON: https://secwatch.observer/filing/0001104659-22-001950.json
- Plain text: https://secwatch.observer/filing/0001104659-22-001950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.